NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Commercial Insight: Multiple Sclerosis - Next generation therapies signal the start of a new era
Introduction
With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).
Scope
*In-depth analysis of the current and future multiple sclerosis therapies across the US, Japan, France, Germany, Italy, Spain and the UK.
*Country-specific total brand sales forecasts for key products, biosimilars and pipeline agents across the seven major markets to 2019.
*Assessment of the commercial opportunities and threats present in the multiple sclerosis market, with analysis of trends in emerging markets.
*Evaluation of the strategies of leading players in the multiple sclerosis disease market.
Highlights
Datamonitor expects Novartis's Gilenia (fingolimod) to launch at the end of 2010 as a first-line therapy, while Merck Serono's oral cladribine is anticipated to launch at the start of 2011. These drugs offer improved efficacy and a less invasive method of administration than current treatments.
Datamonitor expects entry of biosimilar drugs from 2014. The Introduction of cost competition will force current market players to cease raising the price of their drugs above the norm; a strategy that has helped them to substantially increase revenues in recent years.
Novartis is set to usurp Biogen Idec and become the market leading player by the end of the forecast period in 2019. In addition to Gilenia and Extavia (interferon beta 1b), Novartis is developing two multiple sclerosis candidates; PI-230 (Phase I) and BAF312 (Phase II), illustrating its commitment to growing its presence in the marketplace
Reasons to Purchase
*Quantify the current and future size of the multiple sclerosis drug class market and understand the main commercial opportunities and threats
*Assess key marketed and pipeline drugs, including new oral agents, Acorda's Ampyra (dalfampridine) and GW Pharmaceuticals' Sativex (nabiximols).
*Understand the country-specific impact of key events in the multiple sclerosis market during the forecast period 2010 to 2019.
OVERVIEW 1
Catalyst 1
Summary 1
ABOUT DATAMONITOR HEALTHCARE 2
About the central nervous system pharmaceutical analysis team 2
EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the multiple sclerosis market 3
Related reports 4
TABLE OF CONTENTS 5
1. MARKET DEFINITION 6
Market definition for this report 6
2. MARKET OVERVIEW 7
Seven major markets 7
Current market assessment 7
Notable historical growth in multiple sclerosis sales exceeds volume growth from 2005 to 2009 8
The interferons contributed over half of all sales in the multiple sclerosis disease-modifying market in 2009 10
Copaxone outstrips Avonex to become market leader 11
Approved Tysabri continues strong year-on-year growth 12
Future market assessment 13
Key multiple sclerosis brands will undergo strong competition 13
Market value will continue to grow until generic incursion in 2014 13
Pipeline oral disease modifiers will offset generic incursion 14
Opportunities and threats 17
Opportunities 1: efficacious treatment for progressive multiple sclerosis remains a key unmet need 17
Opportunities 2: identifying patients before symptoms emerge 19
Opportunities 3: development of biomarkers will lead to a earlier treatment approach 20
Opportunities 4: targeting symptomatic treatment opens up large patient population 21
Threat 1: biosimilar competition 24
Threat 2: active cost containment set to dampen growth 27
Threat 3: increasing evidence of lack of efficacy for disease-modifying therapies 28
US 28
Current and future market assessment 28
The US multiple sclerosis market captured the largest share of the seven major markets in 2009 28
The US will continue to be the largest of the seven major markets for multiple sclerosis 29
Opportunities and threats 33
Opportunity 1: first oral drugs awarded Fast Track status 33
Opportunity 2: healthcare reform to open up the market for multiple sclerosis developers 34
Threat 1: drug rebates and discounts offset sales growth 35
Threat 2: further tightening of Pharma marketing practices 35
Japan 36
Current and future market assessment 36
Japan is the smallest of the seven major multiple sclerosis markets 36
Launch of Avonex leads to strong growth in 2007-09 37
Approval of Tysabri and Gilenia will boost market growth 37
Opportunities and threats 40
Opportunity 1: Japanese market has considerable Scope for development 40
Opportunity 2: raising awareness of multiple sclerosis will grow market 40
Opportunity 3: elimination of lengthy approval process provides faster approval times 41
Threat 1: biennial price cuts by the Japanese government 41
Five major EU markets (5EU) 41
Current and future market assessment 41
European multiple sclerosis market sales represent strongest growth of the seven major markets 41
Rebif was the Number 1 European multiple sclerosis brand in 2009 42
Pipeline oral drugs to become multiple sclerosis market leaders 43
Opportunities and threats 46
Opportunity 1: innovative drug development encouraged by price premium and high-level reimbursement 46
Opportunity 2: UK market provides Scope for considerable growth 46
Opportunity 3: more extensive UK training of neurologists and better awareness will promote access to therapies 48
Threat 1: Europe's biosimilar pathway is the most advanced in the seven major markets 48
Threat 2: increase in parallel importation threatens drug prices 49
France 51
Current and future market assessment 51
Historical growth driven by Copaxone and Tysabri 51
France to maintain market value 52
Germany 56
Current and future market assessment 56
German multiple sclerosis market is the strongest growing and largest European country 56
German multiple sclerosis market set to remain the largest and most attractive European country 57
Italy 60
Current and future market assessment 60
Italy showed the lowest CAGR of all the major markets from 2005 to 2009 60
Biosimilars will make less impact in Italy than the rest of the European markets 60
Spain 64
Current and future market assessment 64
Multiple sclerosis market in Spain generated $300m in 2009 64
Strong market growth projected to continue 64
UK 68
Current and future market assessment 68
Despite rapid growth, the UK multiple sclerosis market remains the smallest European market 68
Securing NICE approval remains critical to success of pipeline drugs 69
Rest of the world snapshot 73
Current market assessment 73
Rest of world exhibited stronger CAGR than the US 73
Rest of World growth is slower than the seven major markets 73
Rest of the world only represents 17% of global multiple sclerosis sales 75
Despite its small market size, the BRIC countries demonstrated the strongest growth 76
Copaxone is the leading global drug and demonstrates the strongest growth 77
Opportunities and threats 78
Opportunity 1: increasing awareness and treatment of multiple sclerosis in developing countries 78
Threat 1: cost of premium priced multiple sclerosis therapies will restrict growth 78
3. BRAND DYNAMICS 79
Overview of competitive landscape 79
Oral therapies set to outstrip traditional market leaders 79
Patient acquisition process 80
Introduction 80
Patient care path 80
Points of influence in the patient care path 81
Trigger point 1: assessment of the multiple sclerosis activity severity 81
Trigger point 2: disease duration and activity will influence use of biologics 82
Trigger point 3: location of impairments influences type of rehabilitation 84
Drivers of brand choice 84
Disease-modifying efficacy and safety are the most influential factors in prescription 84
Number one influential factor is disease-modifying efficacy 85
Side effects are second major attribute driving brand choice 85
Compliance dependant on efficacy and side effects 86
Disease modifying therapy cost is high 86
US formulary tier status for leading brands 87
Disease modifying multiple sclerosis drugs are in the highest co-payment tiers 88
Trends in marketing strategies 88
Marketing strategy for leading brands 89
Sponsorship/disease awareness campaigns 90
Marketed brands overview - disease-modifying drugs 91
Avonex (interferon beta-1a; Biogen Idec and Genzyme) - the gold standard 92
Drug profile 92
Datamonitor continues to view Avonex as the gold standard 92
Product positioning 93
Avonex is currently the preferred first choice interferon in multiple sclerosis 93
SWOT analysis 94
Brand forecast to 2019 95
Betaseron (interferon beta-1b; Bayer Schering) 97
Drug profile 97
The first multiple sclerosis disease modifier 97
Product positioning 98
Betaseron benefits from historical experience 98
SWOT analysis 98
Brand forecast to 2019 99
Rebif (interferon beta-1a; Merck Serono and Pfizer) 101
Drug profile 101
Product positioning 101
Rebif has superior efficacy compared to Avonex 101
SWOT analysis 103
Brand forecast to 2019 104
Extavia (interferon beta-1a; Novartis) 106
Drug profile 106
Novartis's branded version of interferon beta-1b 106
Product positioning 106
Extavia will establish the ground for Novartis's multiple sclerosis portfolio 106
SWOT analysis 107
Brand forecast to 2019 108
Copaxone (glatiramer acetate; Teva and Sanofi-Aventis) 110
Drug profile 110
Copaxone is biggest selling multiple sclerosis drug 110
Product positioning 111
First-line therapy in competition against interferons 111
SWOT analysis 112
Brand forecast to 2019 113
Tysabri (natalizumab; Biogen Idec and Elan) 115
Drug profile 115
Sale growth continues despite increase in PML cases 115
Product positioning 116
PML risk hinders Tysabri's movement up the treatment algorithm 116
SWOT analysis 117
Brand forecast to 2019 118
Novantrone (mitoxantrone, Merck Serono); 119
Pipeline brands overview 121
Gilenia (fingolimod, Novartis & Mitsubishi Tanabe Pharma) 122
Drug profile 122
First oral drug expected to enter the multiple sclerosis market 122
Development overview 123
Robust clinical trial program strengthens Gilenia's potential 123
Success will depend on risk-benefit ratio of Gilenia 124
Product positioning 126
Gilenia will compete to become first-line therapy 126
SWOT analysis 126
Drug forecast to 2019 127
Oral cladribine (Merck Serono) 128
Drug profile 128
Refusal to file setback delays launch 128
Development overview 129
Favorable annualized relapse reduction rates compared to interferons 129
Phase III trials show impressive efficacy data 130
Product positioning 131
SWOT analysis 131
Drug forecast to 2019 132
Marketed brands overview - key multiple sclerosis-specific symptomatic drugs 134
Ampyra (dalfampridine; Acorda therapeutics) 135
Drug profile 135
First drug approved to help multiple sclerosis patients walk 135
Product positioning 136
Ampyra would be a useful drug for multiple sclerosis, but payers likely to restrict sales 136
Seizure risk necessitates REMS program 137
SWOT analysis 138
Drug forecast to 2019 138
Sativex (nabiximols; GW Pharmaceuticals) 139
Drug profile 139
Development overview 140
Drug evaluation 142
Drug forecast to 2019 142
4. KEY DEVELOPERS 144
Strategic overview 144
Trends in corporate strategy 145
Licensing deals represent an essential tactic to bolster pipeline agents 145
Recent strategic partnerships and deals 146
Abbott acquire Facet Biotech 146
Novartis 147
Corporate strategy 147
Novartis to become the leading multiple sclerosis developer through Gilenia launch 147
Multiple sclerosis portfolio assessment 147
Biogen Idec 148
Corporate strategy 148
Biogen Idec's will remain a leading multiple sclerosis developer through reformulations and novel candidates 148
Multiple sclerosis portfolio assessment 148
Merck Serono 149
Corporate strategy 149
Multiple sclerosis portfolio assessment 149
Teva 150
Corporate strategy 150
Multiple sclerosis portfolio assessment 150
Portfolio assessment of other leading companies 151
Bayer Schering 151
5. CASE STUDIES 152
Introduction 152
Case study 152
Price increases higher than for other autoimmune disorders 152
Price increases in US the highest across the seven major markets 154
BIBLIOGRAPHY 158
Journal papers 158
Websites 159
Other sources 164
Datamonitor reports 164
APPENDIX A - MARKET ASSUMPTIONS 165
Forecasting assumptions 165
New product launches 165
Patent expiries 165
Data definitions, limitations and assumptions 166
Standard units 166
Country group definitions 166
Rest of European Union 166
Middle East and North Africa (MENA) 166
Rest of World 166
Derivation of sales forecasts and pricing trends 166
Forecast methodology 166
Methodology for symptomatic market forecast 167
APPENDIX B 168
Contributing experts 168
Report methodology 168
About Datamonitor 168
About Datamonitor Healthcare 168
About the Central Nervous System analysis team 169
Disclaimer 171
List of Tables
Table 1: Sales and growth of key multiple sclerosis brands across the seven major markets ($m and %), 2009-19 14
Table 2: Sales forecasts of branded multiple sclerosis drugs across the seven major markets ($m), 2009-19 16
Table 3: Summary of opportunities and threats in the multiple sclerosis market across the seven major markets, 2010-19 17
Table 4: Categorization of multiple sclerosis-related symptoms by severity 22
Table 5: Prevalence and treatment of multiple sclerosis symptoms, 2010 23
Table 6: Sales and growth of key multiple sclerosis brands in the US ($m and %), 2009-19 30
Table 7: Sales forecasts of branded multiple sclerosis drugs in the US ($m), 2009-19 32
Table 8: Summary of opportunities and threats in the multiple sclerosis market in the US, 2010-19 33
Table 9: Sales and growth of key multiple sclerosis brands in Japan ($m and %), 2009-19 38
Table 10: Sales forecasts of branded multiple sclerosis drugs in Japan ($m), 2009-19 39
Table 11: Summary of opportunities and threats in the multiple sclerosis market in Japan, 2010-19 40
Table 12: Sales and growth of key multiple sclerosis brands in the five major EU markets ($m and %), 2009-19 44
Table 13: Sales forecasts of branded multiple sclerosis drugs in the five major EU markets ($m), 2009-19 45
Table 14: Summary of opportunities and threats in the multiple sclerosis market in the five major EU markets, 2010-19 46
Table 15: Sales and growth of key multiple sclerosis brands in France ($m and %), 2009-19 53
Table 16: Sales forecasts of branded multiple sclerosis drugs in France ($m), 2009-19 55
Table 17: Sales and growth of key multiple sclerosis brands in Germany ($m and %), 2009-19 57
Table 18: Sales forecasts of branded multiple sclerosis drugs in Germany ($m), 2009-19 59
Table 19: Sales and growth of key multiple sclerosis brands in Italy ($m and %), 2009-19 61
Table 20: Sales forecasts of branded multiple sclerosis drugs in Italy ($m), 2009-19 63
Table 21: Sales and growth of key multiple sclerosis brands in Spain (Sm and %), 2009-19 65
Table 22: Sales forecasts of branded multiple sclerosis drugs in Spain ($m), 2009-19 67
Table 23: Sales and growth of key multiple sclerosis brands in the UK ($m and %), 2009-19 70
Table 24: Sales forecasts of branded multiple sclerosis drugs in the UK ($m), 2009-19 72
Table 25: Global sales dynamics of the multiple sclerosis market by region ($m), 2005-09 74
Table 26: Sales value of multiple sclerosis brands in the US, five major EU markets and the rest of the world ($m), 2005-09 78
Table 27: Sales of leading multiple sclerosis brands in the seven major markets ($m), 2009-19 79
Table 28: Key products in late-stage R&D pipeline for multiple sclerosis, 2010 80
Table 29: Side effects demonstrated by current multiple sclerosis brands, 2010 86
Table 30: Cost analysis of disease-modifying therapies, based on annual cost per patient ($), 2009 87
Table 31: Representative formulary tier status in the US for leading brands in multiple sclerosis, 2010 88
Table 32: Marketing strategies employed by the companies behind the top three multiple sclerosis market brands, 2010 90
Table 33: Avonex (interferon beta-1a; Biogen Idec and Genzyme) - drug profile, 2010 92
Table 34: Key events and launch dates impacting Avonex's revenue forecasts in the seven major markets, 2010-19 95
Table 35: Betaseron (interferon beta-1b; Bayer Schering) - drug profile, 2010 97
Table 36: Key events and launch dates impacting Betaseron's revenue forecasts in the seven major markets, 2010-19 99
Table 37: Rebif (interferon beta-1a; Merck Serono) - drug profile, 2010 101
Table 38: Key events and launch dates impacting Rebif's revenue forecasts in the seven major markets, 2010-19 104
Table 39: Extavia (interferon beta-1b; Novartis) - drug profile, 2010 106
Table 40: Key events and launch dates impacting Extavia's revenue forecasts in the seven major markets, 2010-19 109
Table 41: Copaxone (glatiramer acetate; Teva and Sanofi-Aventis) - drug profile, 2010 110
Table 42: Key events and launch dates impacting Copaxone's revenue forecasts in the seven major markets, 2010-19 114
Table 43: Tysabri (natalizumab; Biogen Idec and Elan) - drug profile, 2010 115
Table 44: Key events and launch dates impacting Tysabri's revenue forecasts in the seven major markets, 2010-19 118
Table 45: Key late-stage multiple sclerosis disease-modifying drug development pipeline, 2010 122
Table 46: Gilenia (fingolimod; Novartis) - drug profile, 2010 123
Table 47: Key ongoing fingolimod multiple sclerosis studies, 2010 123
Table 48: Key events and launch dates impacting Gilenia's revenue forecast for multiple sclerosis in the seven major markets, 2010-19 127
Table 49: Oral cladribine (Merck Serono)- drug profile, 2010 129
Table 50: Key ongoing oral cladribine multiple sclerosis studies, 2010 130
Table 51: Key events and launch dates impacting oral cladribine's revenue forecast for multiple sclerosis in the seven major markets, 2010-19 133
Table 52: Ampyra (dalfampridine; Acorda therapeutics) - drug profile, 2010 135
Table 53: Sativex (nabiximols; GW Pharmaceuticals)- drug profile, 2010 140
Table 54: Leading companies in the seven major multiple sclerosis markets, 2009-19 144
Table 55: Overview of key players with marketed and pipeline drugs in multiple sclerosis market, 2010 145
Table 56: Summary of licensing partnerships of key therapies, 2010 146
Table 57: Novartis's multiple sclerosis portfolio, 2010 147
Table 58: Biogen Idec's key multiple sclerosis portfolio, 2010 148
Table 59: Merck Serono's multiple sclerosis portfolio, 2010 150
Table 60: Teva's multiple sclerosis portfolio, 2010 150
Table 61: Price ($) per dose for multiple sclerosis disease-modifying drugs across the seven major markets ($/SU)*, 2005-09 152
Table 62: Datamonitor's estimated launch dates for multiple sclerosis products in the US, Japan and 5EU, 2009-19 165
Table 63: Anticipated patent expiry dates for multiple sclerosis brands in the US, Japan and 5EU, 2009-19 165
List of Figures
Figure 1: Timeline: launch dates of disease-modifying therapies for treatment of multiple sclerosis, 1993-2009 8
Figure 2: Multiple sclerosis disease-modifying-specific sales in the seven major markets by region ($ billion), 2005-09 9
Figure 3: Multiple sclerosis disease-modifying specific volume sales in the seven major markets by region ($m), 2005-09 10
Figure 4: Multiple sclerosis disease-modifying drug sales by molecule in the seven major markets ($ billion), 2005-09 11
Figure 5: Performance of the key disease-modifying multiple sclerosis therapies in the seven major markets ($m), 2005-09 12
Figure 6: Key events impacting the multiple sclerosis market, 2010-19 13
Figure 7: Sales forecasts for multiple sclerosis market across the seven major markets ($m), 2009-19 15
Figure 8: Relative proportions of multiple sclerosis subtypes 18
Figure 9: Multiple sclerosis prescription volume and sales split by treatment type across the seven major markets, 2010 24
Figure 10: A global perspective on biosimilars, 2010 26
Figure 11: Multiple sclerosis market sales value in US ($m), 2005-09 29
Figure 12: Sales forecasts for multiple sclerosis market in the US ($m),, 2009-19 30
Figure 13: Multiple sclerosis market sales value in Japan ($m), 2005-09 36
Figure 14: Dynamics of the key multiple sclerosis therapies in Japan, 2006-09 37
Figure 15: Sales forecasts for the multiple sclerosis market in Japan ($m), 2009-19 38
Figure 16: Multiple sclerosis market sales value in the five major EU markets ($m), 2005-09 42
Figure 17: Sales forecasts for multiple sclerosis market in the five major EU markets ($m), 2009-19 43
Figure 18: Biosimilar impact on the multiple sclerosis market in the five major EU markets, 2009-19 49
Figure 19: Impact of parallel importation on the German multiple sclerosis market, 2009 50
Figure 20: Price difference per unit of branded multiple sclerosis drugs compared to parallel import in Germany, 2010 50
Figure 21: Multiple sclerosis market sales value in France ($m), 2005-09 52
Figure 22: Sales forecasts for multiple sclerosis market in France ($m), 2009-19 53
Figure 23: Multiple sclerosis market sales value in Germany ($m), 2005-09 56
Figure 24: Sales forecasts for multiple sclerosis market in Germany ($m), 2009-19 58
Figure 25: Multiple sclerosis market sales value in Italy ($m), 2005-09 60
Figure 26: Sales forecasts for multiple sclerosis market in Italy ($m), 2009-19 62
Figure 27: Multiple sclerosis market sales value in Spain ($m), 2005-09 64
Figure 28: Sales forecasts for multiple sclerosis market in Spain ($m), 2005-09 66
Figure 29: Multiple sclerosis market sales value in the UK ($m), 2005-09 69
Figure 30: Sales forecasts for multiple sclerosis market in the UK ($m), 2009-19 71
Figure 31: Global multiple sclerosis market sales value by region ($ billion), 2005-09 73
Figure 32: Global multiple sclerosis market sales dynamics by major region ($m), 2005-09 75
Figure 33: Global multiple sclerosis market sales volume (IMS standard units sold) and sales value ($) by region, 2009 76
Figure 34: Dynamics of the global multiple sclerosis market sales by region ($m), 2005-09 77
Figure 35: UK multiple sclerosis patient care pathway, 2010 81
Figure 36: Treatment of relapse remitting multiple sclerosis (RRMS), 2010 82
Figure 37: Treatment of secondary progressive multiple sclerosis (SPMS), 2010 83
Figure 38: Treatment of primary progressive multiple sclerosis (PPMS), 2010 83
Figure 39: Treatment of primary relapsing multiple sclerosis (PRMS), 2010 84
Figure 40: Key drivers of brand choice for multiple sclerosis 85
Figure 41: Multiple sclerosis marketing process, 2010 89
Figure 42: Support group websites sponsored and run by Multiple Sclerosis drug developers, 2010 91
Figure 43: Position of Avonex (interferon beta-1a) in the multiple sclerosis treatment algorithm, 2010 94
Figure 44: Avonex (interferon beta-1a; Biogen Idec): SWOT analysis in multiple sclerosis (MS), 2010 95
Figure 45: Avonex (interferon beta-1a; Biogen Idec) sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 96
Figure 46: Position of Betaseron (interferon beta-1b) in the multiple sclerosis treatment algorithm, 2010 98
Figure 47: Betaseron (interferon beta-1b, Bayer Schering): SWOT analysis in multiple sclerosis (MS), 2010 99
Figure 48: Betaseron sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 100
Figure 49: Position of Rebif (interferon beta-1a) in the multiple sclerosis treatment algorithm, 2010 103
Figure 50: Rebif (interferon beta-1a, Merck Serono): SWOT analysis in multiple sclerosis (MS), 2010 104
Figure 51: Rebif sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 105
Figure 52: Position of Extavia (interferon beta 1b) in the multiple sclerosis treatment algorithm, 2010 107
Figure 53: Extavia (interferon beta-1b, Novartis): SWOT analysis in multiple sclerosis (MS), 2010 108
Figure 54: Extavia sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 109
Figure 55: Position of Copaxone (Glatiramer acetate) in the multiple sclerosis (MS) treatment algorithm, 2010 111
Figure 56: Copaxone (glatiramer acetate, Teva and Sanofi Aventis): SWOT analysis in multiple sclerosis (MS), 2010 113
Figure 57: Copaxone sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 114
Figure 58: Position of Tysabri (natalizumab) in the multiple sclerosis treatment algorithm, 2010 116
Figure 59: Tysabri (natalizumab, Biogen Idec and Elan): SWOT analysis in multiple sclerosis (MS), 2010 117
Figure 60: Tysabri sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 119
Figure 61: Position of Novantrone (mitoxantrone) in the multiple sclerosis treatment algorithm, 2010 120
Figure 62: Novantrone sales in multiple sclerosis by country in the seven major markets ($m), 2009-19 121
Figure 63: Gilenia (fingolimod, Novartis): SWOT analysis in multiple sclerosis (MS), 2010 126
Figure 64: Datamonitor's forecast sales for Gilenia across the seven major markets for multiple sclerosis ($m), 2011-19 128
Figure 65: Oral cladribine SWOT analysis, 2010 132
Figure 66: Datamonitor's forecast sales for oral cladribine across the seven major markets for multiple sclerosis ($m), 2011-19 134
Figure 67: Ampyra (dalfampridine; Acorda Therapeutics): SWOT analysis, 2010 138
Figure 68: Datamonitor's forecast sales for Ampyra across the seven major markets for multiple sclerosis ($m), 2010-19 139
Figure 69: Phase III study into Sativex on the relief of spasticity due to multiple sclerosis 141
Figure 70: Datamonitor's forecast sales for Sativex (nabiximols; GW Pharmaceuticals) across the seven major markets for multiple sclerosis ($m), 2010-19 143
Figure 71: Price increases of branded multiple sclerosis disease-modifying therapies across the seven major markets (%), 2005-09 153
Figure 72: Price increases of Copaxone compared to key autoimmune brands across the seven major markets (%), 2005-09 154
Figure 73: Average price increases of branded multiple sclerosis disease-modifying therapies by country (%), 2005-09 155
Figure 74: Estimated US sales revenue if drug developers had increased prices in line with inflation compared to historical sales ($m), 2005-09 156
To order this report:
Therapy Industry: Commercial Insight: Multiple Sclerosis - Next generation therapies signal the start of a new era
Check our Company Profile, SWOT and Revenue Analysis!
SOURCE Reportlinker